Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine the benefits of a monitored physical activity program for participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) using a wearable activity device (e.g.fitbit). The goals of this pilot study are to examine 1) whether an incentive is better than no incentive in maintaining an increased level of physical activity and 2) the benefits of physical activity on patient reported disease activity in inflammatory arthritis.
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic, systemic inflammatory disorders affecting 1-2% of the US population. Ongoing chronic inflammation and lack of exercise due to arthritis are each associated with pain, fatigue, depression, muscle loss, obesity, and development of chronic diseases such as cardiovascular disease and diabetes, all of which impact physical functioning and quality of life. Increases in physical activity can significantly impact each one of these outcomes and are likely to positively impact a patients experience of their disease. This study will examine the benefits of a monitored physical activity program. This study will use a wearable activity device (e.g. fitbit) to monitor step counts and will incentivize one group to achieve higher step counts than the control group. The primary goal of this pilot study will be to determine whether one incentive (loss aversion) is better than no incentive in increasing step counts and maintaining an increased level of physical activity.
Additional outcomes of interest are patient reported disease activity (using the RAPID3 patient reported outcome) and physician measured disease activity, quality of life assessments and weight loss.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | No Intervention | Participants will be reimbursed for participation in the study but will not receive other encouragements for meeting fitbit and step count goals | |
| Incentive | Active Comparator | An incentive will be used for this arm to encourage participants to meet their step goals |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Incentive | Other | Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Days Goal Met | The primary outcome will be percent of days meeting goal during the intervention period | 12 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| RAPID3 | Comparison of RAPID3 score and amount of physical activity | 26 Weeks |
| Psoriasis | Physician-assessed psoriasis severity as measured by body surface area (BSA) involved in patients with concurrent psoriasis. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alexis Ogdie-Beatty, MD, MSCE | University of Pennsylvania | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital at the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
The investigators will share the results of the study after completion of the study through publication in a peer-reviewed journal. Investigators wishing to use the de-identified dataset for additional analyses can contact the PI after publication.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015535 | Arthritis, Psoriatic |
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 26 Weeks |
| Patient Feedback | Patient feedback as determined by qualitative surveys taken at Week 14 and Week 26 | 14 Weeks and 26 Weeks |
| Sleep Disturbance and Fatigue | Changes in sleep disturbance and fatigue as determined by PROMIS forms. | 26 Weeks |
| Completion of Activities by Study Participants (Feasibility) | Percentage completion of study activities (weekly questionnaires and transmission of activity into Epic | 26 Weeks |
| D001847 |
| Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D011565 | Psoriasis |
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |